Dingxin Wang1,2, Brian Jin3, Robert Lewandowski3, Robert Ryu3, Kent Sato3, Ann Ragin3, Laura Kulik4, Mary Mulcahy5,6, Frank Miller3, Riad Salem3,6, Andrew Larson3,6, Reed Omary3,6
1Siemens Medical Solutions USA, Inc., Minneapolis, MN, USA; 2Center for Magnetic Resonance Research, University of Minnesota, Minneapolis, MN, USA; 3Department of Radiology, Northwestern University, Chicago, IL, USA; 4Department of Hepatology, Northwestern University, Chicago, IL, USA; 5Department of Medicine, Northwestern University, Chicago, IL, USA; 6Robert H. Lurie Comprehensive Cancer Center, Northwestern University, Chicago, IL, USA
This study accessed the utility of quantitative Transcatheter Intraarterial Perfusion (TRIP)-MRI for predicting chemotherapy-lipiodol delivery during transcatheter arterial chemoembolization (TACE). The volumes of drug distribution in the tumors and liver as well as the selectivity of chemotherapy emulsion delivery to the tumors obtained from pre-TACE TRIP-MRI highly correlated with corresponding parameters seen on CT scans after TACE. These findings suggest that quantitative TRIP-MRI may have the potential to provide important spatial biodistribution information of subsequent drug delivery during liver-directed transarterial locoregional therapies with same catheter positioning.